Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial

by Sodiomon B Sirima, Bernhards Ogutu, John P A Lusingu et al.
Lancet Infect Dis 2016 – Published Online July 15, 2016

11 pp. 302 kB
http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(16)30020-2.pdfcov200h

WHO recommends combinations of an artemisinin derivative plus an antimalarial drug of longer half-life as treatment options for uncomplicated Plasmodium falciparum infection. In Africa, artemether–lumefantrine is the most widely used artemisinin-based combination therapy, whereas artesunate–mefloquine is used infrequently because of a perceived poor tolerance to mefloquine. WHO recommends reconsideration of the use of artesunate–mefloquine in Africa. The authors compared the efficacy and safety of fixed-dose artesunate–mefloquine with that of artemether–lumefantrine for treatment of children younger than 5 years with uncomplicated P falciparum malaria. They conclude that Artesunate–mefloquine is effective and safe, and an important treatment option, for children younger than 5 years with uncomplicated P falciparum malaria in Africa.

(Visited 44 times, 1 visits today)
This entry was posted in General, Malaria, Maternal & Child Health. Bookmark the permalink.